Surgical standards in the management of ovarian cancer

Robert E. Bristow

Research output: Contribution to journalArticle

Abstract

Surgery is the cornerstone of management of epithelial ovarian cancer and has broad applications throughout the clinical course of disease, from initial diagnosis to palliative care. Comprehensive surgical staging is essential for precise prognostic determination and treatment planning for patients with apparent early-stage ovarian cancer. Although randomized trials are lacking, the survival advantage associated with optimal primary cytoreduction has been consistent and reproducible. With increasing radicality of cytoreductive surgical techniques and sophistication of postoperative care, it appears that an "optimal" surgical procedure is that which leaves the patient with no visible residual disease. The survival benefits of cytoreductive surgery are also applicable to women with stage IV ovarian cancer, although the rate of success is somewhat attenuated compared with patients with stage III disease. Recent data also indicate that with appropriate surgical selection criteria, secondary cytoreduction is associated with a significant prolongation of survival for patients with recurrent ovarian cancer. Unfortunately, several recent publications illustrate how the decentralization of health care may have significant ramifications on the ability of women with known or suspected ovarian cancer to avail themselves of the surgical standard of care.

Original languageEnglish (US)
Pages (from-to)474-480
Number of pages7
JournalCurrent Opinion in Oncology
Volume12
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Ovarian Neoplasms
Survival
Postoperative Care
Politics
Standard of Care
Palliative Care
Patient Selection
Delivery of Health Care
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Surgical standards in the management of ovarian cancer. / Bristow, Robert E.

In: Current Opinion in Oncology, Vol. 12, No. 5, 2000, p. 474-480.

Research output: Contribution to journalArticle

Bristow, Robert E. / Surgical standards in the management of ovarian cancer. In: Current Opinion in Oncology. 2000 ; Vol. 12, No. 5. pp. 474-480.
@article{ec9b910d6859439b9863329f7c70b13a,
title = "Surgical standards in the management of ovarian cancer",
abstract = "Surgery is the cornerstone of management of epithelial ovarian cancer and has broad applications throughout the clinical course of disease, from initial diagnosis to palliative care. Comprehensive surgical staging is essential for precise prognostic determination and treatment planning for patients with apparent early-stage ovarian cancer. Although randomized trials are lacking, the survival advantage associated with optimal primary cytoreduction has been consistent and reproducible. With increasing radicality of cytoreductive surgical techniques and sophistication of postoperative care, it appears that an {"}optimal{"} surgical procedure is that which leaves the patient with no visible residual disease. The survival benefits of cytoreductive surgery are also applicable to women with stage IV ovarian cancer, although the rate of success is somewhat attenuated compared with patients with stage III disease. Recent data also indicate that with appropriate surgical selection criteria, secondary cytoreduction is associated with a significant prolongation of survival for patients with recurrent ovarian cancer. Unfortunately, several recent publications illustrate how the decentralization of health care may have significant ramifications on the ability of women with known or suspected ovarian cancer to avail themselves of the surgical standard of care.",
author = "Bristow, {Robert E.}",
year = "2000",
doi = "10.1097/00001622-200009000-00015",
language = "English (US)",
volume = "12",
pages = "474--480",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Surgical standards in the management of ovarian cancer

AU - Bristow, Robert E.

PY - 2000

Y1 - 2000

N2 - Surgery is the cornerstone of management of epithelial ovarian cancer and has broad applications throughout the clinical course of disease, from initial diagnosis to palliative care. Comprehensive surgical staging is essential for precise prognostic determination and treatment planning for patients with apparent early-stage ovarian cancer. Although randomized trials are lacking, the survival advantage associated with optimal primary cytoreduction has been consistent and reproducible. With increasing radicality of cytoreductive surgical techniques and sophistication of postoperative care, it appears that an "optimal" surgical procedure is that which leaves the patient with no visible residual disease. The survival benefits of cytoreductive surgery are also applicable to women with stage IV ovarian cancer, although the rate of success is somewhat attenuated compared with patients with stage III disease. Recent data also indicate that with appropriate surgical selection criteria, secondary cytoreduction is associated with a significant prolongation of survival for patients with recurrent ovarian cancer. Unfortunately, several recent publications illustrate how the decentralization of health care may have significant ramifications on the ability of women with known or suspected ovarian cancer to avail themselves of the surgical standard of care.

AB - Surgery is the cornerstone of management of epithelial ovarian cancer and has broad applications throughout the clinical course of disease, from initial diagnosis to palliative care. Comprehensive surgical staging is essential for precise prognostic determination and treatment planning for patients with apparent early-stage ovarian cancer. Although randomized trials are lacking, the survival advantage associated with optimal primary cytoreduction has been consistent and reproducible. With increasing radicality of cytoreductive surgical techniques and sophistication of postoperative care, it appears that an "optimal" surgical procedure is that which leaves the patient with no visible residual disease. The survival benefits of cytoreductive surgery are also applicable to women with stage IV ovarian cancer, although the rate of success is somewhat attenuated compared with patients with stage III disease. Recent data also indicate that with appropriate surgical selection criteria, secondary cytoreduction is associated with a significant prolongation of survival for patients with recurrent ovarian cancer. Unfortunately, several recent publications illustrate how the decentralization of health care may have significant ramifications on the ability of women with known or suspected ovarian cancer to avail themselves of the surgical standard of care.

UR - http://www.scopus.com/inward/record.url?scp=0034456836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034456836&partnerID=8YFLogxK

U2 - 10.1097/00001622-200009000-00015

DO - 10.1097/00001622-200009000-00015

M3 - Article

C2 - 10975556

AN - SCOPUS:0034456836

VL - 12

SP - 474

EP - 480

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -